UCB SA manufactures and markets innovative pharmaceutical and biotechnological products. The company manufactures prescription drugs and other medicines for central nervous system disorders, allergies, respiratory diseases, cardiovascular diseases, inflammatory disorders, epilepsy, multiple sclerosis and cancer therapy. UCB’s drugs include Keppra® (levetiracetam), an anti-seizure drug, Xyzal® (levocetirizine) and Zyrtec® (cetirizine), an anti-allergic drug, Tussionex™ (hydrocodone polistirex/chlorpheniramine polistirex), an antitussive agent, Nootropil® (piracetam), a cerebral function regulator, Metadate™/Equasym XL™ (methylphenidate) for attention deficit/hyperactivity disorder, and Atarax® (hydroxyzine), a mild tranquillizer.